Please enable JavaScript to continue using this application.

Compare $LYEL vs $WHWK | Chartloom

Compare

$LYEL vs $WHWK

Lyell Immunopharma Inc · Whitehawk Therapeutics Inc

LYEL

Lyell Immunopharma Inc

WHWK

Whitehawk Therapeutics Inc

Compare $LYEL vs $WHWK

Comparing Lyell Immunopharma Inc and Whitehawk Therapeutics Inc

LYELLyell Immunopharma Inc

WHWKWhitehawk Therapeutics Inc

LYELLyell Immunopharma Inc

Market cap

$203M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

16,911.71x

Rev growth (TTM)

-55.0%

YTD performance

-69.9%

52W performance

-52.3%

FCF yield

-86.2%

WHWKWhitehawk Therapeutics Inc

Market cap

$189M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

44.3%

52W performance

65.3%

FCF yield

-36.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LYEL

WHWK

Detailed metrics comparison

LYEL

Lyell Immunopharma Inc

WHWK

Whitehawk Therapeutics Inc

Market Cap

LYEL$203M

WHWK$189M

Enterprise Value

LYEL$130M

WHWK$104M

Price

LYEL$8.71

WHWK$3.52

P/E Ratio

LYELN/A

WHWKN/A

P/S Ratio

LYEL7,526.09x

WHWK7.56x

EV/Sales

LYEL4,822.94x

WHWK0.00x

EV/EBITDA

LYEL0.00x

WHWK0.00x

P/B Ratio

LYEL0.97x

WHWK1.15x

P/FCF Ratio

LYELN/A

WHWKN/A

EV/FCF

LYEL-0.74x

WHWK-1.50x

PEG Ratio

LYELN/A

WHWKN/A

Forward P/E (NTM)

LYELN/A

WHWKN/A

Forward P/S (NTM)

LYEL16,911.71x

WHWKN/A

Revenue (TTM)

LYEL$27K

WHWK$0

Revenue Growth (YoY)

LYEL-55.0%

WHWK-100.0%

Forward Rev Growth

LYEL7184.7%

WHWK167.6%

Gross Margin (TTM)

LYEL0.0%

WHWK88.7%

Operating Margin (TTM)

LYEL0.0%

WHWK87.4%

EBITDA Margin (TTM)

LYEL-669059.3%

WHWK0.0%

Net Margin (TTM)

LYEL-920285.2%

WHWK99.4%

FCF Margin (TTM)

LYEL-648763.0%

WHWKN/A

Net Income (TTM)

LYEL$-248M

WHWK$-80M

FCF (TTM)

LYEL$-175M

WHWK$-69M

EPS (TTM)

LYEL-$10.64

WHWK-$0.96

ROE (TTM)

LYEL-9162.0%

WHWK-5389.0%

ROA (TTM)

LYEL-7050.0%

WHWK-4997.0%

ROIC (TTM)

LYEL-9162.0%

WHWK-5389.0%

Cash

LYEL$73M

WHWK$85M

Debt

LYEL$0

WHWK$0

Net Cash/Debt

LYEL$73M

WHWK$85M

Current Ratio (TTM)

LYEL5.36x

WHWK17.38x

Quick Ratio (TTM)

LYEL5.12x

WHWK17.16x

Debt/Equity (TTM)

LYEL0.00x

WHWK0.00x

Debt/Assets (TTM)

LYEL0.0%

WHWK0.0%

Interest Coverage (TTM)

LYELN/A

WHWKN/A

Net Debt/EBITDA (TTM)

LYEL0.00x

WHWK0.00x

Beta

LYEL-0.04

WHWK0.99

52W Performance

LYEL-52.3%

WHWK65.3%

YTD Performance

LYEL-69.9%

WHWK44.3%

% from 52W High

LYEL-80.6%

WHWK-35.9%

% from 52W Low

LYEL6.1%

WHWK88.2%

Asset Turnover (TTM)

LYEL0.00x

WHWK0.23x

FCF Yield (TTM)

LYEL-86.2%

WHWK-36.6%

Earnings Yield (TTM)

LYEL-122.3%

WHWK-42.2%

Dividend Yield (TTM)

LYELN/A

WHWKN/A

Rule of 40

LYEL-648,818.0

WHWK-100.0

EV/GP/RG

LYELN/A

WHWKN/A

Ticker research

View LYEL research View WHWK research

Metric	LYEL Lyell Immunopharma Inc	WHWK Whitehawk Therapeutics Inc
Market & Valuation
Market Cap	$203M	$189M
Enterprise Value	$130M	$104M
Price	$8.71	$3.52
P/E Ratio	N/A	N/A
P/S Ratio	7,526.09x	7.56x
EV/Sales	4,822.94x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	1.15x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.74x	-1.50x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	16,911.71x	N/A
Revenue & Growth
Revenue (TTM)	$27K	$0
Revenue Growth (YoY)	-55.0%	-100.0%
Forward Rev Growth	7184.7%	167.6%
Profitability
Gross Margin (TTM)	0.0%	88.7%
Operating Margin (TTM)	0.0%	87.4%
EBITDA Margin (TTM)	-669059.3%	0.0%
Net Margin (TTM)	-920285.2%	99.4%
FCF Margin (TTM)	-648763.0%	N/A
Net Income (TTM)	$-248M	$-80M
FCF (TTM)	$-175M	$-69M
EPS (TTM)	-$10.64	-$0.96
ROE (TTM)	-9162.0%	-5389.0%
ROA (TTM)	-7050.0%	-4997.0%
ROIC (TTM)	-9162.0%	-5389.0%
Financial Health
Cash	$73M	$85M
Debt	$0	$0
Net Cash/Debt	$73M	$85M
Current Ratio (TTM)	5.36x	17.38x
Quick Ratio (TTM)	5.12x	17.16x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.04	0.99
52W Performance	-52.3%	65.3%
YTD Performance	-69.9%	44.3%
% from 52W High	-80.6%	-35.9%
% from 52W Low	6.1%	88.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.23x
FCF Yield (TTM)	-86.2%	-36.6%
Earnings Yield (TTM)	-122.3%	-42.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-648,818.0	-100.0
EV/GP/RG	N/A	N/A
Ticker research	View LYEL research	View WHWK research

Valuation

P/S Ratio

WHWK

7.56x

LYEL

7,526.09x

EV/FCF

WHWK

-1.50x

LYEL

-0.74x

Growth & revenue

Revenue Growth TTM

LYEL

-55.0%

WHWK

-100.0%

Forward Revenue Growth

LYEL

7184.7%

WHWK

167.6%

Profitability & performance

Gross Margin

WHWK

88.7%

LYEL

0.0%

ROE

WHWK

-5389.0%

LYEL

-9162.0%

FCF Yield %

WHWK

-36.6%

LYEL

-86.2%

52-Week Performance

WHWK

65.3%

LYEL

-52.3%

Detailed metrics comparison

LYEL

Lyell Immunopharma Inc

WHWK

Whitehawk Therapeutics Inc

Market Cap

LYEL$203M

WHWK$189M

Enterprise Value

LYEL$130M

WHWK$104M

Price

LYEL$8.71

WHWK$3.52

P/E Ratio

LYELN/A

WHWKN/A

P/S Ratio

LYEL7,526.09x

WHWK7.56x

EV/Sales

LYEL4,822.94x

WHWK0.00x

EV/EBITDA

LYEL0.00x

WHWK0.00x

P/B Ratio

LYEL0.97x

WHWK1.15x

P/FCF Ratio

LYELN/A

WHWKN/A

EV/FCF

LYEL-0.74x

WHWK-1.50x

PEG Ratio

LYELN/A

WHWKN/A

Forward P/E (NTM)

LYELN/A

WHWKN/A

Forward P/S (NTM)

LYEL16,911.71x

WHWKN/A

Revenue (TTM)

LYEL$27K

WHWK$0

Revenue Growth (YoY)

LYEL-55.0%

WHWK-100.0%

Forward Rev Growth

LYEL7184.7%

WHWK167.6%

Gross Margin (TTM)

LYEL0.0%

WHWK88.7%

Operating Margin (TTM)

LYEL0.0%

WHWK87.4%

EBITDA Margin (TTM)

LYEL-669059.3%

WHWK0.0%

Net Margin (TTM)

LYEL-920285.2%

WHWK99.4%

FCF Margin (TTM)

LYEL-648763.0%

WHWKN/A

Net Income (TTM)

LYEL$-248M

WHWK$-80M

FCF (TTM)

LYEL$-175M

WHWK$-69M

EPS (TTM)

LYEL-$10.64

WHWK-$0.96

ROE (TTM)

LYEL-9162.0%

WHWK-5389.0%

ROA (TTM)

LYEL-7050.0%

WHWK-4997.0%

ROIC (TTM)

LYEL-9162.0%

WHWK-5389.0%

Cash

LYEL$73M

WHWK$85M

Debt

LYEL$0

WHWK$0

Net Cash/Debt

LYEL$73M

WHWK$85M

Current Ratio (TTM)

LYEL5.36x

WHWK17.38x

Quick Ratio (TTM)

LYEL5.12x

WHWK17.16x

Debt/Equity (TTM)

LYEL0.00x

WHWK0.00x

Debt/Assets (TTM)

LYEL0.0%

WHWK0.0%

Interest Coverage (TTM)

LYELN/A

WHWKN/A

Net Debt/EBITDA (TTM)

LYEL0.00x

WHWK0.00x

Beta

LYEL-0.04

WHWK0.99

52W Performance

LYEL-52.3%

WHWK65.3%

YTD Performance

LYEL-69.9%

WHWK44.3%

% from 52W High

LYEL-80.6%

WHWK-35.9%

% from 52W Low

LYEL6.1%

WHWK88.2%

Asset Turnover (TTM)

LYEL0.00x

WHWK0.23x

FCF Yield (TTM)

LYEL-86.2%

WHWK-36.6%

Earnings Yield (TTM)

LYEL-122.3%

WHWK-42.2%

Dividend Yield (TTM)

LYELN/A

WHWKN/A

Rule of 40

LYEL-648,818.0

WHWK-100.0

EV/GP/RG

LYELN/A

WHWKN/A

Ticker research

View LYEL research View WHWK research

Metric	LYEL Lyell Immunopharma Inc	WHWK Whitehawk Therapeutics Inc
Market & Valuation
Market Cap	$203M	$189M
Enterprise Value	$130M	$104M
Price	$8.71	$3.52
P/E Ratio	N/A	N/A
P/S Ratio	7,526.09x	7.56x
EV/Sales	4,822.94x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	1.15x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.74x	-1.50x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	16,911.71x	N/A
Revenue & Growth
Revenue (TTM)	$27K	$0
Revenue Growth (YoY)	-55.0%	-100.0%
Forward Rev Growth	7184.7%	167.6%
Profitability
Gross Margin (TTM)	0.0%	88.7%
Operating Margin (TTM)	0.0%	87.4%
EBITDA Margin (TTM)	-669059.3%	0.0%
Net Margin (TTM)	-920285.2%	99.4%
FCF Margin (TTM)	-648763.0%	N/A
Net Income (TTM)	$-248M	$-80M
FCF (TTM)	$-175M	$-69M
EPS (TTM)	-$10.64	-$0.96
ROE (TTM)	-9162.0%	-5389.0%
ROA (TTM)	-7050.0%	-4997.0%
ROIC (TTM)	-9162.0%	-5389.0%
Financial Health
Cash	$73M	$85M
Debt	$0	$0
Net Cash/Debt	$73M	$85M
Current Ratio (TTM)	5.36x	17.38x
Quick Ratio (TTM)	5.12x	17.16x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.04	0.99
52W Performance	-52.3%	65.3%
YTD Performance	-69.9%	44.3%
% from 52W High	-80.6%	-35.9%
% from 52W Low	6.1%	88.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.23x
FCF Yield (TTM)	-86.2%	-36.6%
Earnings Yield (TTM)	-122.3%	-42.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-648,818.0	-100.0
EV/GP/RG	N/A	N/A
Ticker research	View LYEL research	View WHWK research